Joseph Scheeren
Prof. Scheeren is an accomplished global executive and leader in R&D and Regulatory Affairs. His pharmaceutical industry career spans more than 35 years in R&D and global leadership positions in the US, Europe and Asia.
He is currently a Non-Executive Director and Board Member of Barinthus Biotherapeutics in the UK, a NASDAQ listed company and Chair of the supervisory Board of C4C S in the Netherlands. He serves on several advisory boards like F-CRIN, CoRE, CIRS and the College of Pharmacy at the University of Arizona. He is a member of the “Academie Nationale de Pharmacie” in France, special advisor to the Critical Path Institute and a fellow of the DIA.
He is an adjunct Professor at Peking University in Regulatory Science and founded the consulting company Scheeren HealthCare LLC in Arizona USA.
He recently served as President and Chief Executive Officer of Critical Path Institute (C- Path), where he shepherded a strategic growth initiative, doubling the size of the organization and its revenue helping to position C-Path for greater impact in multiple areas including neuroscience, immunology, hematology, rare diseases, data management and analytics, building tools to speed up drug development.
Prior to joining C-Path, Prof. Scheeren served in various senior roles at Bayer AG, a global pharmaceutical company, including serving as Senior Vice President, Head of Global Regulatory Affairs, bringing a significant number of novel products in various therapeutic areas, like the blockbusters Xarelto and Eylea, to the global market.
Prof. Scheeren held numerous executive positions at Aventis, HMR, Roussel UCLAF, Ares-Serono and Les Laboratoires Servier.
His former positions include DIA Chair of the Board of Directors, lecturer at Yale University and member of the Forum on Drug Discovery, Development and Translation of the National Academy of Sciences.
Degree(s)
- PharmD, The University of Leiden, Netherlands
- MSc, The University of Leiden, Netherlands
- BS, The University of Leiden, Netherlands